Condition: Vasomotor Symptoms · Sponsor: ApexCPG LLC
This study is to evaluate the effects of CL25216 on vasomotor symptoms in women during Perimenopause. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.
This description comes directly from the study's public registry record.
Mr. T.V.N. Rao · +91 8331015069 · tvnrao.apex@gmail.com
Always discuss trial participation with your own doctor first.
| Shree Hospitals | Vijayawada, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07112651